GlassScriptPhysician profile
Gururau Sudarshan
NPI 1326046871
$20,330.88
in general payments reported to CMS, 2019-2025
39 companies · $2,648 in 2025
The $2,648 reported for 2025 was more than what 87% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,815 · 2020: $1,315 · 2021: $1,438 · 2022: $6,051 · 2023: $2,386 · 2024: $4,677 · 2025: $2,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,319 · Travel and Lodging: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,319.05 |
| Travel and Lodging | $1,392.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,141.63 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Synchromedii |
| Abbott Laboratories | $2,692.12 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $2,019.16 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Clinical Trial Product |
| Vertos Medical, INC. | $1,909.66 | 2020-2024 | Mild Device Kit |
| Stryker Corporation | $1,507.84 | 2023-2025 | Mild Device Kit, Spinejack, Optablate |
| Spinal Simplicity, LLC | $1,066.89 | 2021-2022 | |
| Saluda Medical Americas, INC. | $501.38 | 2024-2025 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.83 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Nevro Corp. | $363.96 | 2019-2021 | |
| Abbvie INC. | $290.03 | 2021-2025 | Qulipta, Ubrelvy |
| Spr Therapeutics, INC | $216.01 | 2024-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $206.84 | 2020-2025 | Belbuca, Xtampza |
| Medtronic USA, INC. | $194.26 | 2019-2020 | |
| Biotronik Nro, INC. | $193.71 | 2025 | Prospera |
| Curonix LLC | $177.43 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $147.64 | 2022 | |
| Painteq LLC | $113.00 | 2023-2024 | Painteq |
| Nalu Medical, INC. | $93.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $89.63 | 2019-2020 | |
| Stimwave Technologies Incorporated | $82.60 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $73.31 | 2023-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $67.49 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $67.35 | 2025 | |
| Averitas Pharma INC. | $67.20 | 2025 | Qutenza |
| Arbor Pharmaceuticals, INC. | $57.22 | 2019-2021 | |
| Daiichi Sankyo INC. | $53.84 | 2019 | |
| Pfizer INC. | $53.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $50.38 | 2019-2020 | |
| Globus Medical, INC. | $46.86 | 2025 | Omnia |
| Kaleo, INC. | $41.42 | 2019 | |
| Assertio Therapeutics, INC. | $40.75 | 2019 | |
| Si-Bone, INC. | $40.01 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $36.69 | 2022 | |
| Amgen INC. | $29.69 | 2022 | |
| Bioventus LLC | $29.27 | 2019-2022 | |
| Ethicon US, LLC | $23.00 | 2024 | Stratafix |
| Tersera Therapeutics LLC | $22.56 | 2024 | Prialt |
| Almatica Pharma LLC | $14.75 | 2021 | |
| Biodelivery Sciences International, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gururau Sudarshan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.